Click here to discover the largest collection of GeneMedi's Promise-ORF™ ORF/cDNA expression clones
- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected]
Protocol Library Download
 |
 |
Human SLC1A5/AAAT/ASCT2 ORF/cDNA clone-Mammalian (Non-Viral Vector) plasmid (NM_005628.2)
Cat. No.: pGMPC001496
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human SLC1A5/AAAT/ASCT2 Non-Viral expression plasmid (overexpression vector) for mouse SLC1A5 overexpression in unique cell transient transfection and stable cell line development.
Datasheet
Go to
SLC1A5/ASCT2/SLC1A5/AAAT products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
| Catalog ID | pGMPC001496 |
| Gene Name | SLC1A5 |
| Accession Number | NM_005628.2 |
| Gene ID | 6510 |
| Species | Human |
| Product Type | Mammalian (Non-Viral Vector) plasmid (overexpression) |
| Insert Length | 1626 bp |
| Gene Alias | AAAT,ASCT2,ATBO,M7V1,M7VS1,R16,RDRC |
| Fluorescent Reporter | Null |
| Mammalian Cell Selection | Null |
| Fusion Tag | Null |
| Promoter | CMV |
| Resistance | Amplicin |
| ORF Nucleotide Sequence | ATGGTGGCCGATCCTCCTCGAGACTCCAAGGGGCTCGCAGCGGCGGAGCCCACCGCCAACGGGGGCCTGGCGCTGGCCTCCATCGAGGACCAAGGCGCGGCAGCAGGCGGCTACTGCGGTTCCCGGGACCAGGTGCGCCGCTGCCTTCGAGCCAACCTGCTTGTGCTGCTGACAGTGGTGGCCGTGGTGGCCGGCGTGGCGCTGGGACTGGGGGTGTCGGGGGCCGGGGGTGCGCTGGCGTTGGGCCCGGAGCGCTTGAGCGCCTTCGTCTTCCCGGGCGAGCTGCTGCTGCGTCTGCTGCGGATGATCATCTTGCCGCTGGTGGTGTGCAGCTTGATCGGCGGCGCCGCCAGCCTGGACCCCGGCGCGCTCGGCCGTCTGGGCGCCTGGGCGCTGCTCTTTTTCCTGGTCACCACGCTGCTGGCGTCGGCGCTCGGAGTGGGCTTGGCGCTGGCTCTGCAGCCGGGCGCCGCCTCCGCCGCCATCAACGCCTCCGTGGGAGCCGCGGGCAGTGCCGAAAATGCCCCCAGCAAGGAGGTGCTCGATTCGTTCCTGGATCTTGCGAGAAATATCTTCCCTTCCAACCTGGTGTCAGCAGCCTTTCGCTCATACTCTACCACCTATGAAGAGAGGAATATCACCGGAACCAGGGTGAAGGTGCCCGTGGGGCAGGAGGTGGAGGGGATGAACATCCTGGGCTTGGTAGTGTTTGCCATCGTCTTTGGTGTGGCGCTGCGGAAGCTGGGGCCTGAAGGGGAGCTGCTTATCCGCTTCTTCAACTCCTTCAATGAGGCCACCATGGTTCTGGTCTCCTGGATCATGTGGTACGCCCCTGTGGGCATCATGTTCCTGGTGGCTGGCAAGATCGTGGAGATGGAGGATGTGGGTTTACTCTTTGCCCGCCTTGGCAAGTACATTCTGTGCTGCCTGCTGGGTCACGCCATCCATGGGCTCCTGGTACTGCCCCTCATCTACTTCCTCTTCACCCGCAAAAACCCCTACCGCTTCCTGTGGGGCATCGTGACGCCGCTGGCCACTGCCTTTGGGACCTCTTCCAGTTCCGCCACGCTGCCGCTGATGATGAAGTGCGTGGAGGAGAATAATGGCGTGGCCAAGCACATCAGCCGTTTCATCCTGCCCATCGGCGCCACCGTCAACATGGACGGTGCCGCGCTCTTCCAGTGCGTGGCCGCAGTGTTCATTGCACAGCTCAGCCAGCAGTCCTTGGACTTCGTAAAGATCATCACCATCCTGGTCACGGCCACAGCGTCCAGCGTGGGGGCAGCGGGCATCCCTGCTGGAGGTGTCCTCACTCTGGCCATCATCCTCGAAGCAGTCAACCTCCCGGTCGACCATATCTCCTTGATCCTGGCTGTGGACTGGCTAGTCGACCGGTCCTGTACCGTCCTCAATGTAGAAGGTGACGCTCTGGGGGCAGGACTCCTCCAAAATTACGTGGACCGTACGGAGTCGAGAAGCACAGAGCCTGAGTTGATACAAGTGAAGAGTGAGCTGCCCCTGGATCCGCTGCCAGTCCCCACTGAGGAAGGAAACCCCCTCCTCAAACACTATCGGGGGCCCGCAGGGGATGCCACGGTCGCCTCTGAGAAGGAATCAGTCATGTAA |
| ORF Protein Sequence | MVADPPRDSKGLAAAEPTANGGLALASIEDQGAAAGGYCGSRDQVRRCLRANLLVLLTVVAVVAGVALGLGVSGAGGALALGPERLSAFVFPGELLLRLLRMIILPLVVCSLIGGAASLDPGALGRLGAWALLFFLVTTLLASALGVGLALALQPGAASAAINASVGAAGSAENAPSKEVLDSFLDLARNIFPSNLVSAAFRSYSTTYEERNITGTRVKVPVGQEVEGMNILGLVVFAIVFGVALRKLGPEGELLIRFFNSFNEATMVLVSWIMWYAPVGIMFLVAGKIVEMEDVGLLFARLGKYILCCLLGHAIHGLLVLPLIYFLFTRKNPYRFLWGIVTPLATAFGTSSSSATLPLMMKCVEENNGVAKHISRFILPIGATVNMDGAALFQCVAAVFIAQLSQQSLDFVKIITILVTATASSVGAAGIPAGGVLTLAIILEAVNLPVDHISLILAVDWLVDRSCTVLNVEGDALGAGLLQNYVDRTESRSTEPELIQVKSELPLDPLPVPTEEGNPLLKHYRGPAGDATVASEKESVM |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Biosimilar | GMP-Bios-ab-260 | Pre-Made Idactamab biosimilar, Whole mAb, Anti-SLC1A5 Antibody: Anti-AAAT/ASCT2/ATBO/M7V1/M7VS1/R16/RDRC therapeutic antibody |
| Target Antibody | GM-Tg-g-T59493-Ab | Anti-AAAT/ SLC1A5/ ASCT2 monoclonal antibody |
| Target Antigen | GM-Tg-g-T59493-Ag | SLC1A5 VLP (virus-like particle) |
| ORF Viral Vector | pGMLV001142 | Human SLC1A5 Lentivirus plasmid |
| ORF Viral Vector | pGMLV002011 | Human SLC1A5 Lentivirus plasmid |
| ORF Viral Vector | pGMAD000187 | Human SLC1A5 Adenovirus plasmid |
| ORF Viral Vector | pGMAD000450 | Human SLC1A5 Adenovirus plasmid |
| ORF Viral Vector | pGMPC001496 | Human SLC1A5 Mammalian (Non-Viral Vector) plasmid |
| ORF Viral Vector | vGMLV001142 | Human SLC1A5 Lentivirus particle |
| ORF Viral Vector | vGMLV002011 | Human SLC1A5 Lentivirus particle |
| ORF Viral Vector | vGMAD000187 | Human SLC1A5 Adenovirus particle |
| ORF Viral Vector | vGMAD000450 | Human SLC1A5 Adenovirus particle |
Target information
| Target ID | GM-T59493 |
| Target Name | SLC1A5/ASCT2 |
|
Gene Group Identifier （Target Gene ID in Homo species) |
6510 |
| Gene ID |
100146913 (Equus caballus), 101090567 (Felis catus), 20514 (Mus musculus), 282355 (Bos taurus) 292657 (Rattus norvegicus), 484425 (Canis lupus familiaris), 6510 (Homo sapiens), 716843 (Macaca mulatta) |
| Gene Symbols & Synonyms | SLC1A5,Slc1a5,R16,AAAT,ATBO,M7V1,RDRC,ASCT2,M7VS1,Slc1a7,Asct2,ATB(0),H4-ASCT2 |
| Target Alternative Names | AAAT,ASCT2,ATB(0),ATBO,Asct2,Baboon M7 virus receptor,H4-ASCT2,M7V1,M7VS1,Neutral amino acid transporter B(0),R16,RD114/simian type D retrovirus receptor,RDRC,SLC1A5,Slc1a5,Slc1a7,Sodium-dependent neutral amino acid transporter type 2,Solute carrier family 1 member 5 |
| Uniprot Accession |
D3ZJ25,P51912,Q15758,Q95JC7
Additional SwissProt Accessions: P51912,Q95JC7,D3ZJ25,Q15758 |
| Uniprot Entry Name | |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | |
| Disease from KEGG | Protein digestion and absorption, Central carbon metabolism in cancer |
| Gene Ensembl | ENSECAG00000011637, ENSMUSG00000001918, ENSBTAG00000013577, ENSCAFG00845003284, ENSG00000105281, ENSMMUG00000022163 |
| Target Classification |
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.